GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » Revenue

CADL (Candel Therapeutics) Revenue : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics Revenue?

Candel Therapeutics's revenue for the three months ended in Dec. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Candel Therapeutics's Revenue per Share for the three months ended in Dec. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Candel Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -17.00% per year. The lowest was -17.00% per year. And the median was -17.00% per year.


Candel Therapeutics Revenue Historical Data

The historical data trend for Candel Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Candel Therapeutics Revenue Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial 0.13 0.13 0.13 - -

Candel Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Candel Therapeutics's Revenue

For the Biotechnology subindustry, Candel Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Candel Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's Revenue falls into.


;
;

Candel Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Candel Therapeutics  (NAS:CADL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Candel Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Candel Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Executives
Paul Peter Tak director, officer: President & CEO CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Francesca Barone officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan officer: See Remarks CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Paul B Manning director 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Estuardo Aguilar-cordova director, officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Nicoletta Loggia director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello officer: Chief Financial Officer 500 KENDALL STREET, CAMBRIDGE MA 01824
Christopher Martell director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta director C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Nathan Caffo officer: Chief Business Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
John J Canepa officer: Chief Financial Officer 241 MATTINSON DRIVE, CONCORD MA 01742